# Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema

> **NCT05728476** · NA · RECRUITING · sponsor: **Tianjin Medical University Eye Hospital** · enrollment: 102 (estimated)

## Conditions studied

- Diabetic Macular Edema
- Pars Plana Vitrectomy
- Conbercept

## Interventions

- **PROCEDURE:** Vitrectomy combined with ILM peeling
- **DRUG:** Conbercept intravitreal injection

## Key facts

- **NCT ID:** NCT05728476
- **Lead sponsor:** Tianjin Medical University Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2025-09-05
- **Final completion:** 2026-09-05
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728476, "Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05728476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*